NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球止痛藥市場 第5版:市場動向、R&D考察

The Global Pain Therapeutics Market, 6th Edition: Market Trends and R&D Insights

出版商 Arrowhead Publishers 商品編碼 363527
出版日期 內容資訊 英文 585 Pages
商品交期: 最快1-2個工作天內
價格
全球止痛藥市場 第5版:市場動向、R&D考察 The Global Pain Therapeutics Market, 6th Edition: Market Trends and R&D Insights
出版日期: 2019年02月01日內容資訊: 英文 585 Pages
簡介

本報告針對全球止痛藥市場進行調查,彙整市場動向、課題、業界主要企業檔案、臨床開發階段及已上市主要產品的最新狀況等內容提供如後。

第1章 執行摘要

第2章 疼痛:疾病背景

  • 疼痛簡介
  • 疼痛的分類
  • 疼痛的流行病學
  • 免疫系統與疼痛
  • 疼痛與遺傳學
  • 疼痛的主觀性質
  • 疼痛的全球性影響

第3章 疼痛管理:WHO的止痛藥分級與治療指南

  • WHO的止痛藥分類概要
  • M01A 非類固醇抗發炎藥物 (NSAID)
  • M01B 抗發炎性/抗風濕藥的組合
  • N01A 全身麻醉劑
  • N01B 局部麻醉劑
  • N02A 麻醉劑止痛藥
  • N02B 非麻醉劑止痛藥
  • N02C 抗偏頭痛藥
  • Arrowhead的止痛藥分類系統
  • WHO的疼痛管理指南

第4章 手術後疼痛市場

  • 手術後疼痛概要
  • 手術後疼痛的流行病學
  • 術後止痛管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第5章 神經性疼痛市場

  • 神經性疼痛概要
  • 神經性疼痛的流行病學
  • 神經性疼痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第6章 纖維肌痛市場

  • 纖維肌痛概要
  • 纖維肌痛的流行病學
  • 纖維肌痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第7章 關節痛市場

  • 關節痛概要
  • 關節痛的流行病學
  • 關節痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第8章 偏頭痛市場

  • 偏頭痛概要
  • 偏頭痛的流行病學
  • 偏頭痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第9章 癌症疼痛市場

  • 癌症疼痛概要
  • 癌症疼痛的流行病學
  • 癌症止痛管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第10章 腰痛市場

  • 腰痛概要
  • 腰痛的流行病學
  • 腰痛的治療管理
  • 主力品牌
  • 未滿足需求
  • 開發平台分析
  • 市場說明

第11章 止痛藥物的研究開發趨勢

  • 簡介:變化的需求
  • 臨床實驗概要
  • R&D的生物標記
  • 疼痛的個人化醫療
  • 止痛標的選擇、評估
  • 動物疼痛模式
  • 健康的人體中實驗疼痛模式
  • 功能性影像技術
  • 美國保健機關對疼痛研發變更的調查結果與推廣
  • 止痛藥物的研發未來
  • 對抗FDA的類鴉片物質的濫用的配合措施

第12章 疼痛治療藥市場上未滿足需求

  • 目前止痛藥的需求高漲中的臨床性效果
  • 目前疼痛治療藥的安全性不穩定
  • 類鴉片物質的濫用
  • 忽視某種程度的疼痛患者人口
  • 投藥療法的改善
  • 便利性高的給藥途徑
  • 動物疼痛模式的有效性
  • 疼痛評估模式的可靠性
  • 利害關係人教育的欠缺

第13章 對疼痛治療藥開發平台的關注

第14章 疼痛治療藥市場分析

第15章 企業概要

第16章 參考文獻

目錄

Despite two decades of intensive R&D effort, pain continues to present major clinical, social and economic challenges. Globally, one in five people suffer from moderate-to-severe chronic pain. Chronic pain affects 100 million US adults, more than heart disease, cancer and diabetes combined.

Despite two decades of intensive R&D effort, pain continues to present major clinical, social and economic challenges. Globally, one in five people suffer from moderate-to-severe chronic pain. Chronic pain affects 100 million US adults, more than heart disease, cancer and diabetes combined. The annual cost of chronic pain in the US ranges from $560 to $635 billion. Current analgesics only provide limited pain relief, frequently carry black box safety warnings and are susceptible to abuse. Indeed, the US opioid abuse problem is described as a 'growing deadly epidemic' and a 'national emergency'. There is a clear need for novel, safe therapies that treat various types of pain. This new report from Arrowhead Publishers analyzes the current market landscape for new pain therapy entrants. The hotly anticipated arrival of abuse-deterrent opioids and monoclonal antibodies such as CGRP and JAK inhibitors should help revitalize the market for pain therapies.

THIS IN-DEPTH, QUALITY REPORT DELIVERS:

  • Analysis of seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and clinical/commercial pipeline analysis of each condition to maximize your product's commercial success
  • Identification of the major challenges within pain R&D including unmet needs, clinical trial design, alternative R&D approaches, potential pain biomarkers, animal pain models, functional imaging techniques and regulatory hurdles
  • A financial assessment of the pain market with forecasts to 2023 for over 70 leading branded analgesic products and key pipeline candidates

REPORT HIGHLIGHTS:

In 2018, the leading branded pain therapeutics market will generate a massive $26.3 billion, down 30.3% from 2017 total leading branded revenues of $37.8 billion. The 2018 patent expiry of Pfizer's Lyrica (pregablin) contributed towards this revenue loss.

Opioids will continue to form the backbone of pain management over the coming years due to their superior analgesic action. Worryingly though, between 1999 and 2016, the number of opioid overdose deaths has increased by five times from around 8,000 to 42,000, respectively. With the FDA prioritizing abuse-deterrent opioids, newcomers such as Egalet-002, NKTR-181and oxycodone ER will aid physician confidence and market growth.

Pain R&D is challenging, expensive and reliant on subjective outcome measures. Therefore, industry must revise their R&D strategies to gain success in this market. The FDA's 2014 Draft Guidance for Industry Analgesic Indications: Developing Drug and Biological Products should provide some clarity for pain developers.

Key questions answered by Arrowhead's Global Pain Therapeutics Market, 6th Edition: Market Trends and R&D Insights include:

  • What are the major unmet needs in the current pain market?
  • What are the leading potential pain biomarkers?
  • What are the major challenges involved in the pain market and how can they be overcome?
  • Who are the key players involved in the pain market and what business models are they using to raise company performance?
  • How can players optimize strategic pain R&D to maximize commercial success?
  • What recommendations does Arrowhead provide for successful pain R&D?
  • Which analgesics have gained FDA approval in recent years?
  • What are the leading branded pain therapeutics available on the market?
  • What are the key leading therapeutic candidates in the pain pipeline?
  • How much revenue will the leading branded analgesic products reach by 2023?
  • How much revenue will the key pipeline drug candidates reach by 2023?
  • What does the future hold for the pain market?

Table of Contents

1 Executive Summary

  • 1.1 Scope of Global Pain Therapeutics Market, 6th Edition: Market Analysis and Pipeline Insights
  • 1.2 Methodology of Global Pain Therapeutics Market, 6th Edition: Market Analysis and Pipeline Insights
  • 1.3 The Epidemiology of Pain in the Seven Major Markets
  • 1.4 Unmet Needs in the Pain Therapeutics Market
  • 1.5 Pain Therapeutics Pipeline Analysis
  • 1.6 Pain Therapeutics Market Analysis

2 Pain: Disease Background

  • 2.1 An Introduction to Pain
  • 2.2 The Classification Of Pain
    • 2.2.1 Acute Pain
    • 2.2.2 Chronic Pain
  • 2.3 The Pathophysiology Of Pain
    • 2.3.1 The Pain Pathway
    • 2.3.2 The Modulation of the Pain Signal
    • 2.3.3 Referred Pain
  • 2.4 The Immune System and Pain
    • 2.4.1 Nerve Growth Factor (NGF)
    • 2.4.2 Brain Derived Neurotrophic Factor (BDNF)
    • 2.4.3 Nitrous Oxide (NO)
    • 2.4.4 Tumor Necrosis Factor (TNF)
    • 2.4.5 Interleukin-1 (IL-1)
    • 2.4.6 Interleukin-6 (IL-6)
    • 2.4.7 Glutamate
  • 2.5 Pain and Genetics
  • 2.6 The Subjective Nature Of Pain
    • 2.6.1 The Evaluation of Pain
  • 2.7 The Global Impact of Pain
    • 2.7.1 The Financial Impact of Pain

3 Managing Pain: WHO'S Pain Therapeutics Classes And Treatment Guidelines

  • 3.1 Overview of The Who's Pain Therapeutics Classification
  • 3.2 M01A Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • 3.3 M01B Anti-Inflammatory/Anti-Rheumatic Agents in Combination
  • 3.4 N01A General Anesthetics
  • 3.5 N01B Local Anesthetics
  • 3.6 N02A Narcotic Analgesics
  • 3.7 N02B Non-Narcotic Analgesics
  • 3.8 N02C Anti-Migraine Preparations
  • 3.9 Arrowhead's Analgesic Drug Classification System
  • 3.10 WHO Pain Management Guidelines

4 The Postoperative Pain Market

  • 4.1 Overview of Postoperative Pain
  • 4.2 Epidemiology of Postoperative Pain
  • 4.3 The Therapeutic Management of Postoperative Pain
    • 4.3.1 Epidural Local Anesthetics Used in Postoperative Pain
    • 4.3.2 Strong Opioids Used in Postoperative Pain
    • 4.3.3 Weak Opioids Used in Postoperative Pain
    • 4.3.4 NSAIDs Used in Postoperative Pain
    • 4.3.5 Multi-Modal Analgesia Used in Postoperative Pain
  • 4.4 Leading Brand Products in the Postoperative Pain Market
    • 4.4.1 Janssen Pharmaceuticals' Duragesic (transdermal fentanyl)
    • 4.4.2 Pacira Pharma's Exparel (bupivacaine liposome injection)
    • 4.4.3 Pfizer's Dyloject (injectable diclofenac)
  • 4.5 Unmet Needs in the Postoperative Pain Market
  • 4.6 Postoperative Pain Therapeutics Pipeline Analysis
    • 4.6.1 Durect Corporation/Sandoz's Posimir (SABER-bupivacaine)
    • 4.6.2 Trevena's Olinvo (Oliceridine Injection, TRV130)
    • 4.6.3 Adynxx's Brivoligide (AYX1)
    • 4.6.4 AcelRx Pharmaceuticals' Dsuvia (sufentanil)
    • 4.6.5 Lumosa Therapeutics/InteRx Biomedical's ' Naldebain ( LT-1001)
    • 4.6.6 Heron Therapeutics' HTX-011(bupivacaine/meloxicam ER)
  • 4.7 Postoperative Pain Therapeutics Market Commentary

5 The Neuropathic Pain Market

  • 5.1 Overview of Neuropathic Pain
  • 5.2 Epidemiology of Neuropathic Pain
  • 5.3 The Therapeutics Management of Neuropathic Pain
    • 5.3.1 Topical Lidocaine Used in Neuropathic Pain
    • 5.3.2 Anticonvulsants Used in Neuropathic Pain
    • 5.3.3 Opioids Used in Neuropathic Pain
  • 5.4 Leading Brand Products in the Neuropathic Pain Market
    • 5.4.1 Endo Pharmaceuticals' Lidoderm (lidocaine 5% patch)
    • 5.4.2 Pfizer's Lyrica (pregablin)
    • 5.4.3 Eli Lilly's Cymbalta (duloxetine)
    • 5.4.4 Pfizer's Neurontin (gabapentin)
    • 5.4.5 Collegium Pharma/Depomed's Nucynta ER (tapentadol-er)
    • 5.4.6 Acorda Therapeutics/Grüenthal's Qutenza (capsaicin 8% patch)
    • 5.4.7 Depomed's Gralise (gabapentin-er)
  • 5.5 Unmet Needs in the Neuropathic Pain Market
  • 5.6 Neuropathic Pain Therapeutics Pipeline Analysis
  • 5.7 Daiichi Sankyo's Mirogabalin (DS-5565)
    • 5.7.2 Biogen's Vixotrigine (BIIB074)
  • 5.8 Novartis' Olodanrigan (EMA401)
    • 5.8.1 Calchan's CNV-2197944
    • 5.8.2 ViroMed/VM BioPharma's Donaperminogene Seltoplasmid (VM202)
  • 5.9 Neuropathic Pain Therapeutics Market Commentary

6 The Fibromyalgia Market

  • 6.1 Fibromyalgia Overview
  • 6.2 Epidemiology of Fibromyalgia
  • 6.3 The Therapeutic Management of Fibromyalgia Pain
    • 6.3.1 Analgesics Used in Fibromyalgia
    • 6.3.2 Antidepressants Used in Fibromyalgia
    • 6.3.3 Muscle Relaxants Used in Fibromyalgia
    • 6.3.4 Sleep Modifiers Used in Fibromyalgia
    • 6.3.5 Anxiety Medications Used in Fibromyalgia
    • 6.3.6 Anticonvulsants Used in Fibromyalgia
    • 6.3.7 Antibiotics Used in Fibromyalgia
  • 6.4 Leading Brands in the Fibromyalgia Pain Market
    • 6.4.1 Pfizer's Lyrica (pregabalin)
    • 6.4.2 Allergan/Forest Laboratories 'Savella (milnacipran)
    • 6.4.3 Eli Lilly's Cymbalta (duloxetine)
  • 6.5 Unmet Needs in the Fibromyalgia Pain Market
  • 6.6 Fibromyalgia Pain Pipeline Analysis
    • 6.6.1 Innovative Med Concepts' IMC-1
    • 6.6.2 Meiji Seika Pharma's Mirtazapine
  • 6.7 Fibromyalgia Pain Market Commentary

7 The Arthritic Pain Market

  • 7.1 Arthritis Overview
  • 7.2 Epidemiology of Arthritic Pain
  • 7.3 The Therapeutic Management of Arthritic Pain
    • 7.3.1 Acetaminophen used in Arthritis
    • 7.3.2 NSAIDs Used in Arthritis
    • 7.3.3 COX-2 Inhibitors Used in Arthritis
    • 7.3.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs) Used in Arthritis
    • 7.3.5 Biologic Disease Modifying Anti-inflammatory Drugs Used in Arthritis
    • 7.3.6 Corticosteroids Used in Arthritis
    • 7.3.7 Immunosuppressants used in Arthritis
  • 7.4 Leading Brands in the Arthritic Pain Market
    • 7.4.1 AbbVie's Humira (adalimumab)
    • 7.4.2 Genentech/Roche/Biogen's Rituxan/MabThera (rituximab)
    • 7.4.3 Amgen/Pfizer's Enbrel (etanercept)
    • 7.4.4 Johnson & Johnson/Merck's Remicade (infliximab)
    • 7.4.5 Pfizer's Celebrex (celecoxib)
    • 7.4.6 Pfizer's Arthrotec (diclofenac/misprostol)
    • 7.4.1 Horizon Pharma/AstraZeneca/Pozen 's Vimovo (naproxen/esomeprazole)
    • 7.4.2 Boehringer Ingelheim/Abbott's Mobic (meloxicam)
    • 7.4.3 Pfizer's DayPro (oxarprozin)
    • 7.4.4 Pfizer's Xeljanz (tofacitinib)
  • 7.5 Unmet Needs in the Arthritic Pain Market
  • 7.6 Arthritic Pain Therapeutic Pipeline Analysis
    • 7.6.1 Galapagos NV/Gilead Science's Filgotinib (GLPG0634)
    • 7.6.2 Astellas'Peficitinib (ASP015K)
    • 7.6.3 Vitaeris' Clazakizumab (ALD518)
    • 7.6.4 AbbVie's Upadacitinib (ABT-494)
    • 7.6.5 Centrexion Therapeutics' CNTX-4975 (trans capsaicin)
    • 7.6.6 Eli Lilly's Taltz (ixekizumab)
  • 7.7 Eli Lilly/Pfizer's Tanezumab
  • 7.8 Arthritic Pain Market Commentary

8 The Migraine Market

  • 8.1 Migraine Overview
  • 8.2 Epidemiology of Migraine
  • 8.3 The Therapeutic Management of Migraine
    • 8.3.1 Prophylactic Migraine Therapies
    • 8.3.2 Basic Analgesics Used in Migraine
    • 8.3.3 Ergot Alkaloid Derivatives Used in Migraine
    • 8.3.4 Triptans Used in Migraine
    • 8.3.5 Neuroleptics Used in Migraine
    • 8.3.6 Beta-Blockers Used in Migraine
  • 8.4 Leading Brand Products in the Migraine Market
    • 8.4.1 GSK's Imitrex/Imigran (sumatriptan)
    • 8.4.2 Impax Laboratories/Grüenthal's Zomig (zolmitriptan)
    • 8.4.3 Merck's Maxalt (rizartriptan)
    • 8.4.4 Pfizer's Relpax (eletriptan)
    • 8.4.5 Pernix Therapeutics/Pozen's Treximet (sumatripatan/naproxen)
    • 8.4.6 Janssen's Topamax (topiramate)
    • 8.4.7 AbbVie's Depakote (divalproex)
    • 8.4.8 Allergan's Botox (onabotulinumtoxinA)
    • 8.4.9 Amgen/Novartis' Aimovig (erenumab)
  • 8.5 Unmet Needs in the Migraine Market
  • 8.6 Migraine Therapeutics Pipeline Analysis
    • 8.6.1 Eli Lilly's Lasmiditan (COL-144)
    • 8.6.2 Alder Biopharmaceuticals' Eptinezumab (ALD403)
    • 8.6.3 Teva Pharmaceuticals' Fremanezumab (TEV-48125)
    • 8.6.4 Eli Lilly's Emgality (galcanezumab)
    • 8.6.5 Allergan's Ubrogepant (MK-1602)
    • 8.6.6 Biohaven Pharmaceuticals' Rimegepant (BHV-3000)
  • 8.7 Migraine Market Commentary

9 The Cancer Pain Market

  • 9.1 Cancer Pain Overview
  • 9.2 Epidemiology of Cancer Pain
  • 9.3 The Therapeutic Management of Cancer Pain
    • 9.3.1 Strong Opioids Used in Cancer Pain
    • 9.3.2 Weak Opioids Used in Cancer Pain
    • 9.3.3 NSAIDs and Acetaminophen Used in Cancer Pain
    • 9.3.4 Adjuvants Used in Cancer Pain
  • 9.4 Leading Brands in the Cancer Pain Market
    • 9.4.1 Teva/Cephalon's Actiq (oral transmucosal fentanyl)
    • 9.4.2 Teva's Fentora (fentanyl buccal)
    • 9.4.3 Purdue's OxyContin (oxycodone)
    • 9.4.4 Kyowa Kirin/Sentynl Therapeutics/Orexo's Abstral (fentanyl sublingual)
    • 9.4.5 Insys Therapeutics' Subsys (sublingual fentanyl)
  • 9.5 Unmet Needs in the Cancer Pain Therapeutics Market
  • 9.6 Cancer Pain Therapeutics Pipeline Analysis
    • 9.6.1 Wex Pharmaceuticals' Halneuron (tetrodotoxin)
    • 9.6.2 Tetra Bio-Pharma's PPP001 (9.5% THC, 2.5% CBD)
    • 9.6.3 Eli Lilly/Pfizer's Tanezumab
  • 9.7 Cancer Pain Therapeutics Market Commentary

10 The Back Pain Market

  • 10.1 Back Pain Overview
  • 10.2 Epidemiology of Back Pain
  • 10.3 The Therapeutic Management of Back Pain
    • 10.3.1 NSAIDs Used in Back Pain
    • 10.3.2 Transdermal Patches Used in Back Pain
    • 10.3.3 Local Anesthetics Used in Back Pain
    • 10.3.4 Opioids Used in Back Pain
    • 10.3.5 Tricyclic Antidepressants Used in Back Pain
    • 10.3.6 Muscle Relaxants Used in Back Pain
    • 10.3.7 Colchicine Used in Back Pain
    • 10.3.8 Anticonvulsants Used in Back Pain
  • 10.4 Leading Brand Products in the Back Pain Market
    • 10.4.1 Bayer's Aleve (naproxone)
    • 10.4.2 Novartis/GSK/Endo Pharma' Voltaren (diclofenac)
    • 10.4.3 Pfizer's Advil (ibuprofen)
    • 10.4.4 BMS' Efferalgan (acetaminophen)
    • 10.4.5 Johnson &Johnson's Tyenol (acetaminophen)
  • 10.5 Unmet Needs in the Back Pain Market
  • 10.6 Back Pain Pipeline Analysis
    • 10.6.1 Axsome Therapeutics' AXS-02 (zoledronate)
    • 10.6.2 Mesoblast's MPC-016 -ID
    • 10.6.3 Semnur Pharmaceuticals' SP-102
    • 10.6.4 Nektar Therapeutics' NKTR-181
  • 10.7 Eli Lilly/Pfizer's Tanezumab
  • 10.8 Back Pain Market Commentary

11 Pain Therapeutics Research and Development (R&D) Trends

  • 11.1 Introduction to Pain R&D: The Need for Change
  • 11.2 Overview of Clinical Trials
    • 11.2.1 The Triad of Successful Pain Clinical Trials
    • 11.2.2 Issues Surrounding Analgesic Clinical Trial Design
  • 11.3 Biomarkers in R&D
    • 11.3.1 Predictive Biomarkers as Clinical Trial Surrogate Endpoints
    • 11.3.2 The Use of Biomarkers to Stratify Patients
    • 11.3.3 Potential Pain Biomarkers
  • 11.4 Personalized Medicine in Pain
  • 11.5 Analgesic Target Selection and Validation
  • 11.6 Animal Pain Models
  • 11.7 Experimental Pain Models in Healthy Humans
    • 11.7.1 UV-B Pain Model
    • 11.7.2 Heat/Capsaicin Sensitization and Intradermal Capsaicin Injection Models
    • 11.7.3 Multi-Modal, Multi-Tissue Model
    • 11.7.4 Quantitative Sensory Testing
    • 11.7.5 Current Perception Threshold (CPT)
  • 11.8 Functional Imaging Techniques
    • 11.8.1 Functional Magnetic Resonance Imaging (fMRI)
    • 11.8.2 Positron Emission Tomography (PET)
    • 11.8.3 Single-Photon Emission Computed Tomography (SPECT)
    • 11.8.4 Laser Doppler Flowmetry (LDF)
  • 11.9 US Health Agencies Findings and Recommendations for Change in Pain R&D
    • 11.9.1 Institute of Medicine Committee on Advancing Pain Research, Care and Education
    • 11.9.2 The NIH Pain Consortium
    • 11.9.3 Arrowhead's Recommendations for Maximizing Pain Therapeutics R&D
  • 11.10 The Future of Pain R&D
  • 11.11 FDA'S Efforts to Combat Opioid Misuse and Abuse
    • 11.11.1 Abuse-Deterrent Formulations
    • 11.11.2 Abuse Liability and Safety/ Risk Evaluation and Mitigation Strategy (REMS)

12 Unmet Needs in the Pain Therapeutics Market

  • 12.1 Clinical Efficacy of Today's Analgesics Need Improving
  • 12.2 Safety Profiles of Current Pain Therapeutics are Often Unacceptable
  • 12.3 Opioid Misuse and Abuse
  • 12.4 Certain Pain Patient Populations are Neglected
  • 12.5 Improved Dosing Regimens
  • 12.6 Convenient Administration Routes
  • 12.7 The Validity of Animal Pain Models
  • 12.8 The Reliability of Pain Evaluation Models
  • 12.9 Lack of Stakeholder Education

13 Pain Therapeutics Pipeline Watch

  • 13.1 Introduction to the Pain Therapeutics Pipeline
  • 13.2 Targeted Therapies
    • 13.2.1 Pfizer's Tanezumab (PF-4383119)
  • 13.3 NAV Ion Channel Modulators
    • 13.3.1 Biogen's Vixotrigine (BIIB074)
    • 13.3.2 Vertex Pharma's VX-150
    • 13.3.3 Xenon/Genentech's GDC-0310
  • 13.4 Transient Receptor Potential (TPR) Channel Modulators
    • 13.4.1 TRPV1 Agonists
      • 13.4.1.1 Sorrento Therapeutics' Resiniferatoxin (RTX)
      • 13.4.1.2 Centrexion Therapeutics' CNTX-4975 (trans capsaicin)
    • 13.4.2 TRP Antagonists
    • 13.4.2.1 Neomed Institutes' NEO6860
  • 13.5 Purinoreceptor (P2X3 Receptor) Antagonists
  • 13.6 Glutatmate Receptor Antagonists
    • 13.6.1 NMDA-Receptor Antagonists
    • 13.6.2 NDMA and Opioid Receptor Overlap
  • 13.7 Dual MU-Opioid Agonist and Nor Epinephrine Reuptake Inhibitors
  • 13.8 Imidazoline I2 Receptors
  • 13.9 Microglia Inhibitors
  • 13.10 Kappa Opioid Receptor Antagonists
  • 13.11 A3 Adenosine Receptor Agonists
  • 13.12 Abuse-Deterrent Opioids
    • 13.12.1 Nektar Therapeutics' NKTR-181
    • 13.12.2 Intellipharmaceutics'Oxycodone ER
    • 13.12.3 Egalet's Egalet-002

14 Analysis of the Pain Therapeutic Market

  • 14.1 Summary of Arrowhead's Pain Therapeutics Analysis, 2018
  • 14.2 Leading Pain Therapeutic Products of 2017
  • 14.3 Leading Pain Therapeutics Drug Classes of 2017
  • 14.4 Leading Pain Therapeutics Drug Class Products of 2017
    • 14.4.1 COX-2 Inhibitors: Pfizer's Celebrex (celecoxib)
    • 14.4.2 NSAIDs: Pfizer's Advil (ibuprofen)
    • 14.4.3 Local Anesthetics: Pacira's Exparel (bupivacaine liposome Injection)
    • 14.4.4 Opioids: Purdue's OxyContin (oxycodone)
    • 14.4.5 Triptans: Pfizer's Relpax (eletriptan)
    • 14.4.6 Non-traditional: AbbVie's Humira (adalimumab)
  • 14.5 Pfizer: Arrowhead's Leading Pain Therapeutics Company of 2017
  • 14.6 SWOT Analysis of the Pain Therapeutics Market
  • 14.7 Financial Forecast of the Branded Pain Therapeutics Market
  • 14.8 Arrowhead'd NSAID Market Outlook
    • 14.8.1 Drivers and Constraints of the NSAID Market
    • 14.8.2 Financial Forecast of the NSAID Market
  • 14.9 Arrowhead'd Cox-2 Market Outlook
    • 14.9.1 Drivers and Constraints of the COX-2 Market
    • 14.9.2 Financial Forecast of the COX-2 Market ($m)
  • 14.10 Arrowhead'd Opioid Market Outlook
    • 14.10.1 Drivers and Constraints of the Opioid Market
    • 14.10.2 Financial Forecast of the Opioid Market
  • 14.11 Arrowhead's Triptan Market Outlook
    • 14.11.1 Drivers and Constraints of the Triptan Market
    • 14.11.2 Financial Forecast of the Triptan Market
  • 14.12 Arrowhead's Non-Traditional/Adjuvant Market Outlook
    • 14.12.1 Drivers and Constraints of the Non-Traditional/Adjuvant Pain Therapeutic Market
    • 14.12.2 Financial Forecast of the Non-Traditional/Adjuvant Market
  • 14.13 Arrowhead's Local Anesthetics Market Outlook
    • 14.13.1 Drivers and Constraints of the Local Anesthetic Market
    • 14.13.2 Financial Forecast of the Local Anesthetics Market
  • 14.14 Summary of the Future Global Pain Therapeutics Market

15 Company Briefs

  • 15.1 Abbvie INc.
  • 15.2 Acelrx Pharmaceuticals Inc.
  • 15.3 Adynnx
  • 15.4 Alder Biopharmaceuticals Inc.
  • 15.5 Allergan PLC
  • 15.6 Astellas Pharmaceuticals Inc.
  • 15.7 Axsome Therapeutics Inc.
  • 15.8 Biohaven Pharmaceuticals Holding Company Ltd.
  • 15.9 Biogen Inc.
  • 15.10 Calchan Ltd.
  • 15.11 Centrexion Therapeutics Corp.
  • 15.12 Daiichi Sankyo Company Ltd.
  • 15.13 Durect Corporation
  • 15.14 Egalet Corporation
  • 15.15 Eli Lilly & Company
  • 15.16 Galapagos NV
  • 15.17 Genentech Inc.
  • 15.18 Gilead Sciences Inc.
  • 15.19 Heron Therapeutics
  • 15.20 Immune Pharmaceuticals
  • 15.21 Innovative Med Concepts Inc.
  • 15.22 Intelipharmaceutics International Inc.
  • 15.23 Lumosa Therapeutics Co. Ltd.
  • 15.24 Meiji Seka Pharma Co. Ltd.
  • 15.25 Mesoblast Ltd.
  • 15.26 Nektar Therapeutics
  • 15.27 Neomed Institute
  • 15.28 Novartis International AG
  • 15.29 Pfizer Inc.
  • 15.30 Semnur Pharmaceuticals Inc.
  • 15.31 Sorrento Therapeutics Inc.
  • 15.32 Tetra Biopharma
  • 15.33 TEVA Pharmaceuticals Industries
  • 15.34 Trevena Inc.
  • 15.35 Vertex Pharmaceuticals Inc.
  • 15.36 Viromed Co. Ltd.
  • 15.37 Vitaeris Inc.
  • 15.38 Wex Pharmaceuticals Inc.
  • 15.39 Xenon Pharmaceuticals Inc.